Floatz logo

Ciml-Nk Cells

Juvenile Myelomonocytic Leukemia

Dana-Farber Cancer InstituteCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

28 Active assets in the Juvenile Myelomonocytic Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
Phase 4BBB
Thiotepa
St. Jude Children's Research Hospital
Phase 3BBB
Busulphan
Masonic Cancer Center, University of Minnesota
Phase 4BBB
Fludarabine
Children's Oncology Group
Phase 3BB
FILGRASTIM
Masonic Cancer Center, University of Minnesota
Phase 3BB

View all 46 →

Same molecule, other indications

Ciml-Nk Cells is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
56 / 100
View asset →
myeloproliferative neoplasmDormant
CC
Indicative ·
41 / 100
View asset →
myelodysplastic syndromeDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →